Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 8 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Cobolimab with dostarlimab and docetaxel for advanced non-small-cell lung cancer after anti-PD-L1 therapy and chemotherapy	Cobolimab , Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Dostarlimab (TSR-042; Jemperli)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Darolutamide in addition to docetaxel and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer	Darolutamide (ODM-201; BAY-1841788; Nubeqa) , Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous)	Prostate cancer	Male Reproductive Cancer	2021	View \| Download
Durvalumab with fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer	5-Fluorouracil , Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Leucovorin , Oxaliplatin	Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2023	View \| Download
Nivolumab in combination with rucaparib for chemotherapy naive metastatic castration-resistant prostate cancer	Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Enzalutamide (Xtandi; MDV3100) , Nivolumab (Opdivo; BMS-936558; ONO-4538) , Rucaparib (Rubraca; PF-1367338)	Prostate cancer	Male Reproductive Cancer	2019	View \| Download
Nivolumab in combination with rucaparib for metastatic castration-resistant prostate cancer with prior chemotherapy	Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Enzalutamide (Xtandi; MDV3100) , Nivolumab (Opdivo; BMS-936558; ONO-4538) , Rucaparib (Rubraca; PF-1367338)	Prostate cancer	Male Reproductive Cancer	2019	View \| Download
Nivolumab with docetaxel for advanced castration-resistant prostate cancer	Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Prostate cancer	Male Reproductive Cancer	2021	View \| Download
Pembrolizumab in addition to docetaxel for chemotherapy-naive metastatic castration-resistant prostate cancer – second line	Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Pembrolizumab (Keytruda; MK-3475)	Prostate cancer	Male Reproductive Cancer	2020	View \| Download
Plinabulin in addition to docetaxel for advanced, metastatic non-small-cell lung cancer - second line or greater	Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Plinabulin (BPI-2358)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download

About

Devices, Diagnostics & Digital

About

Data Science & AI

Devices, Diagnostics & Digital

Insights (Public/Patient)

Medicines

Medicine Industry's Gateway to NICE

Support for Industry

Outputs & Publications